Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective...

Area of Science:

• Medicinal Chemistry
• Epigenetics
• Cancer Biology

Background:

• Bromodomain-containing Protein 4 (BRD4) is an epigenetic reader crucial for regulating chromatin structure and gene expression.
• BRD4's role in promoting tumor gene expression (e.g., c-Myc, NF-κB, Bcl-2) makes it a significant therapeutic target for various cancers.
• Targeting BRD4 offers a promising strategy for developing novel anti-cancer therapies.

Purpose of the Study:

• To design and synthesize novel 3-methyl-1H-indazole derivatives as potential inhibitors of BRD4.
• To evaluate the inhibitory activities of these compounds against BRD4-BD1.
• To assess the antiproliferative effects of the synthesized compounds on cancer cell lines.

Main Methods:

• Virtual screening and structure-based optimization were employed for compound design.
• Synthesis of a new series of 3-methyl-1H-indazole derivatives.
• In vitro assays to determine BRD4-BD1 inhibition and antiproliferative activity against cancer cell lines.

Main Results:

• Several synthesized compounds, including 9d, 9u, and 9w, displayed significant BRD4-BD1 affinity and inhibitory activity.
• These compounds effectively suppressed the proliferation of the MV4;11 cancer cell line.
• Compound 9d exhibited high selectivity for BRD4 and demonstrated potent suppression of c-Myc, a key downstream target.

Conclusions:

• The study identified novel 3-methyl-1H-indazole derivatives with potent BRD4 inhibitory and antiproliferative activities.
• Compound 9d emerged as a promising lead candidate due to its selectivity and efficacy in suppressing a critical oncogenic pathway.
• These findings provide a foundation for further development of BRD4-targeted cancer therapeutics.